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Platinum-based chemotherapy doublets have been the standard approach to first-line
therapy for more than a decade. Many randomized trials testing new combinations have
not been able to produce significant gains in patient outcomes when these studies have
looked at an unselected patient population. The recognition of the biologic importance
of histology and molecular features of lung cancer has dramatically impacted on patient
care, as can be easily recognized by the advent of targeted therapy for molecularly defined
lung cancers. Similarly, for lung cancers without recognized driver mutations, subgroup
evaluations of trials-based histology has identified that some chemotherapy regimens offer
greater benefit in the squamous cell or the non-squamous cell groups.Two such examples
are nab-paclitaxel and pemetrexed. These have shown improved anti-tumor activity and a
decreased toxicity profile compared to standard combinations. Preferential activity in histo-
logic divided patient subgroups can allow the clinician to personalize his approach to care.
The role of these two agents in the management of NSCLC will be described in this article.
Keywords: metastatic, non-small cell lung carcinoma, solvent-based paclitaxel, nab-paclitaxel, pemetrexed,
histology, clinical trials
INTRODUCTION
The standard of care for the first-line treatment of advanced
NSCLC without epidermal growth factor receptor (EGFR) or
anaplastic lymphoma kinase (ALK) mutations (about 80% of
advanced NSCLC) remains a platinum-based doublet in patients
with good performance status (PS) and no significant comor-
bidities. This includes third-generation cytotoxic agents (i.e., cis-
platin plus gemcitabine or carboplatin plus paclitaxel) (1, 2). Until
recently no platinum doublet has demonstrated superiority over
another in the treatment of advanced NSCLC (3–10). Lately, his-
tology has been shown to affect the treatment outcomes (1).
Patients with non-squamous cell cancer (NSCC) currently have
a variety of first-line treatment options (1). Testing for EGFR
and ALK mutations and tailoring therapy accordingly are now
accepted as a standard practice in patients with NSCLC (1). For
these patients, current guidelines recommend targeted therapies as
first-line treatment (1). However, about 60–90%, varying largely
according to ethnicity and smoking status, of patients with NSCLC
have wild-type EGFR. Several studies have demonstrated that
EGFR mutations occur infrequently in patients with squamous cell
carcinoma (11–14). ALK mutations/fusions have been observed
in only 1–7% of patients (15–20). Because EGFR and ALK muta-
tions occur infrequently in patients with squamous cell NSCLC,
mutation testing is not recommended routinely with the excep-
tion of never smokers and mixed histologies (1, 21, 22). Overall,
for patients with EGFR and Alk unmutated NSCLC, platinum-
based chemotherapy regimens remain the standard of care in
first-line therapy (1). Key phase III studies reporting outcomes
with platinum-doublet regimens for patients with squamous his-
tology have demonstrated a median overall survival (OS) ranging
from 8.9 to 13.7 months (5, 23–26) whereas the NSCC population
fared slightly better with an OS of 10.4–14.9 months. Similarly,
recently reported trials have renewed the interest in adapting
treatment based on histology. Two key examples of potential
application of personalized therapy based on histology are nab-
paclitaxel, which has shown improved results in the squamous
cell cancer (SCC) population and pemetrexed, which has on the
contrary, shown clear benefit in the NSCC patients. This mini-
review will highlight these two unique drugs and how they can
be incorporated into practice to improve outcomes in NSCLC
therapy.
PEMETREXED
Pemetrexed is a folic acid derivative that inhibits both purine and
pyrimidine synthesis by blocking three key metabolic enzymes
involved in DNA synthesis: thymidylate synthase (TS), dihy-
drofolate reductase (DHFR), and glycinamide ribonucleotide
formyltransferase (GARFT) (27). Building on the efficacy of
methotrexate in many human cancers, research focusing on the
identification of more potent inhibitors of purine synthesis has
led to the identification of the promising activity of peme-
trexed in lung cancer in the late 1990s (27). Although several
hundred trials have been conducted to evaluate the efficacy of
pemetrexed in many cancer settings, the first pivotal study was
reported by Hanna in 2004 (28). It is interesting to note that at
this time in pemetrexed development, studies were conducted
in unselected patient populations with NSCLC. Emerging sci-
ence since 2003 (29) and in particular the study published by
Ceppi et al. (30) in 2006, identified that chemonaïve patients with
squamous carcinoma had tumors expressing higher levels of TS
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than patients with adenocarcinoma. These seminal studies led
to the re-evaluation of previously published as well as ongoing
randomized trials to evaluate the interaction of histology with
clinical efficacy in NSCLC. The demonstration of a consistent
effect in NSCC and the lack of effect in SCC (Table 1) has
eventually directed the registration process for pemetrexed use
and dictated its current clinical use, which is now restricted to
non-squamous histology. Interestingly, knowledge of anti-folate
metabolism has also been able to decrease the incidence of
pemetrexed toxicity by the addition of folic acid and vitamin B12
supplementation (31).
SECOND-LINE STUDIES
Initially published in 2004 (28) as a study showing similar efficacy
between pemetrexed and docetaxel in unselected patients with
NSCLC, Hanna et al. presented a subgroup analysis based on his-
tology at the 12th WCLC in Seoul, Korea in 2007. The reported
median OS in the NSCC population was 9.2 vs. 8.2 months (peme-
trexed vs. docetaxel) and this was respectively 6.2 vs. 7.4 months
in the SCC cohort. This translates to an adjusted HR for OS of
0.78 in favor of pemetrexed in the NSCC group and a HR of 1.56
in the SCC group. Results were similar for PFS, with the HR being
0.82 in the NSCC group and 1.40 in the SCC group. The statistical
test demonstrating a quantitative interaction was positive for OS
(p= 0.001) and PFS (p= 0.004) (32).
MAINTENANCE STUDIES
Three large randomized,placebo-controlled trials address the issue
of pemetrexed maintenance and are discussed in the article of
this issue of Frontiers related to maintenance therapy. As the
PARAMOUNT (33) and AVAPERL (34) study are composed of
an exclusively NSCC population, only JMEN is informative as
to the histological interaction of pemetrexed therapy in this set-
ting. The JMEN study, published in 2009 by Ciuleanu (35) was
reported as a positive trial in an unselected population. The PFS
after first-line therapy was 4.3 months in the pemetrexed group
and 2.6 months in the placebo group (HR 0.50, p< 0.001). The
corresponding OS values were 13.4 and 10.6 months (HR 0.79,
p= 0.012). To validate, the biologic relevance of the histologic
interaction previously observed in the Hanna study, Belani et al.
reported this subgroup analysis at ASCO in 2009. This analysis
convincingly supported the previously observed finding of a his-
tological effect. Whereas PFS was indeed favorably impacted in
the NSCC population (HR 0.47, p< 0.0001), this was not the
case for SCC (HR 1.03, p= 0.90). Similar findings were found
for OS (HR 0.70, p= 0.002 and HR 1.07, p= 0.68). From this
moment on, pemetrexed use in the setting of SCC decreased
substantially. The histologic effect of pemetrexed was major con-
tributors to the major revolution in lung cancer care. A diagnosis of
NSCLC (non-otherwise specified) is now considered suboptimal
for patient care.
FIRST-LINE STUDIES
The JMDB study compared pemetrexed plus cisplatin with
gemcitabine plus cisplatin in patients with advanced NSCLC
(5). Similarly with other previously conducted trials evaluating
pemetrexed, patients of all histologies were accrued to this trial
that was published before the widespread acceptance of a clear
histologic effect. Whereas, the overall study results did not appear
to favor the pemetrexed plus cisplatin combination (OS HR
0.94, p=NS), subgroup analysis based on histology did show
once again a significant interaction. The gemcitabine regimen
produced a significantly longer median OS compared with
pemetrexed regimen in patients with SCC (10.8 vs. 9.4 months,
HR 1.23, p= 0.05). The opposite was seen in patients with
NSCC (10.4 vs. 11.8 months, HR 0.84, p= 0.011). Similarly,
PFS was impacted in a similar manner in the SCC group (HR
1.36, p= 0.002) and the NSCC group (HR 0.95, p= 0.35). The
treatment-by-histology interaction test was positive for PFS and
for OS.
One outlier in the pemetrexed–histology interaction story is
the Gronberg trial published in 2009 (36). This smaller study
Table 1 | Pemetrexed-histology interaction in randomized clinical trials of NSCLC.
First-line therapy
(n=1725)
Maintenance therapy
(N=663)
Second-line therapy
(N=571)
Squamous
(N=473)
Non-squamous
(N=1252)
Squamous
(N=182)
Non-squamous
(N=481)
Squamous
(N=172)
Non-squamous
(N=399)
Overall survival
Adjusted HR 1.23 0.84 1.07 0.70 1.56 0.78
Superiority p 0.050 0.011 0.678 0.002 0.018 0.048
Interaction test p 0.002 0.033 0.001
Progression-free survival
Adjusted HR 1.36 0.95 1.03 0.47 1.40 0.82
Superiority p 0.002 0.349 0.896 <0.001 0.046 0.076
Interaction test p 0.002 0.036 0.004
Adapted from Scagliotti et al. (32).
Hazard ratio <1 favors pemetrexed in non-squamous subgroups of all three studies.
Hazard ratio (HR)>1.0 favors comparator arm in squamous subgroups of all three studies.
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included 436 patients, including 248 patients with NSCC histology.
Median OS was 7.3 months in the pemetrexed with carboplatin
arm compared to 7.0 months in the gemcitabine with carboplatin
arm (p= 0.63). Subgroup analysis was respectively 7.8 vs. 7.5 in
patients with NSCC (p= 0.77) and not reported for the SCC
subgroup. This trial was not designed to evaluate RR or PFS as
radiological assessment was not mandatory. These seemingly infe-
rior results may be due to the patient population, which included
22% of patients with PS 2 status, to the upfront 25% decrease in
pemetrexed dose in the 18% of the population that was>75 years
of age, to the use of carboplatin instead of cisplatin, or to the small
sample size of this study.
Although the combination of carboplatin with pemetrexed
and bevacizumab has never been formally compared with stan-
dard cisplatin and pemetrexed, the PointBreak (37) study com-
pared another standard regimen – carboplatin plus paclitaxel and
bevacizumab compared with carboplatin with pemetrexed and
bevacizumab. This extensive, 939-patient, exclusively-NSCC trial
failed to show a clearly superior regimen in terms of efficacy. The
HR for OS was 1.00 and for PFS was 0.83 (p= 0.012) slightly
favoring the pemetrexed triplet. The contribution of bevacizumab
to a platinum-pemetrexed doublet has never been studied in a
randomized trial.
SAFETY AND TOLERABILITY
The study by Hanna et al. (28) provides a good opportunity to
compare pemetrexed and docetaxel’s toxicity profile. In this study,
Grade 3–4 hematologic toxicities were significantly worse with
docetaxel: neutropenia (40.2 vs. 5.3%), febrile neutropenia (12.7
vs. 1.9%), compared to pemetrexed.
Non-hematologic toxicities (all grades) were relatively similar
except for alopecia (37.7 vs. 6.4%) and diarrhea (24.3 vs. 12.8%)
more frequently observed with docetaxel and ALT elevations (1.4
vs. 7.9%) more frequent with pemetrexed.
Relevant to second-line therapy decisions, there have been no
large randomized trial comparing pemetrexed alone and an EGFR
inhibitor in the second-line setting. A small phase II randomized
trial did compare pemetrexed to erlotinib in EGFR mutation-
negative but EGFR–FISH positive NSCLC (38). Although effi-
cacy differences could not be demonstrated between both regi-
mens, toxicity analysis did provide interesting observations. Few
Grade 3–4 toxicities were described. For erlotinib and pemetrexed,
respectively, rash was present in 3.3 and 0%; diarrhea in 1.6 and
0%; anorexia in 1.6 and 0%, and nausea in 0 and 3.2% (38). Com-
pared to placebo in the Ciuleanu maintenance trial, patients having
received four courses of a first-line platinum containing doublet
rarely developed Grade 3–4 toxicities (all <5%) while on peme-
trexed alone. The most frequent toxicities (mostly Grade 1–2) were
fatigue (24 vs. 10%), anorexia (19 vs. 2%), and nausea (19 vs. 5%);
all compared to placebo.
The first difference between cisplatin with pemetrexed and cis-
platin with gemcitabine is its administration schedule in that the
latter regimen requires a second visit to the chemotherapy suite
on day 8 whereas the former is a day 1 infusion alone. The JMDB
trial also showed some differences in the Grade 3–4 toxicity profile
of both combinations. Compared with the pemetrexed regimen,
the gemcitabine doublet was associated with more neutropenia
(26.7 vs. 15.1%), febrile neutropenia (3.7 vs. 1.3%), anemia (7.6
vs. 4.8%) and thrombocytopenia (12.7 vs. 4.1%), and less anorexia
(0.7 vs. 2.4%) and nausea (3.9 vs. 7.2%).
In the Gronberg trial, the use of pemetrexed and carboplatin
was associated with less granulocytopenia (40 vs. 51%) and throm-
bocytopenia (24 vs. 56%) compared to carboplatin and gemc-
itabine. This was associated with a decrease in the transfusion of
red blood cell (29 vs. 43%) and platelet (3 vs. 9%) transfusions
with pemetrexed use (5).
The PointBreak trial showed clinically relevant differences in
the Grade 3–4 toxicities of the studied regimens. The pemetrexed
arm was associated with more anemia (14.5 vs. 2.7%), throm-
bocytopenia (23.3 vs. 5.6%), and fatigue (10.9 vs. 5.0%) whereas
neutropenia (40.6 vs. 25.8%), febrile neutropenia (4.1 vs. 1.4%),
sensory neuropathy (4.1 vs. 0%), and alopecia (36.8 vs. 6.6%)
occurred more frequently in the paclitaxel triplet (37).
CONCLUSION
Pemetrexed use has shown consistent effects in favor of its
use in the setting of non-squamous cell lung cancer. Com-
pared with paclitaxel, gemcitabine, or docetaxel, its favorable
efficacy, toxicity profile, and convenient schedule of adminis-
tration makes this an agent of choice in this setting. As dis-
cussed in the article of this journal on maintenance therapy,
data from the PARAMOUNT and AVAPERL trial lends increasing
support for the first-line use of pemetrexed and its considera-
tion for maintenance in non-progressing patients after induction
therapy.
NAB-PACLITAXEL
Nab-paclitaxel is a 130 nm, albumin-bound formulation of the
microtubule inhibitor paclitaxel (39), and is a solvent-free option
for the first-line treatment of advanced NSCLC (39).
Solvents such as Cremophor EL and polysorbate 80 require
specialized tubing for administration, which is not required
for the administration of nab-paclitaxel (39–42). These solvents
have intrinsic toxicities, i.e., hypersensitivity reactions requiring
steroid/antihistamine pre-treatments, neuropathy, and excessive
fluid retention (40, 43, 44). In a pre-clinical study, nab-paclitaxel
demonstrated both enhanced endothelial cell binding and trans-
port, and improved delivery of paclitaxel to tumors compared with
solvent-based paclitaxel (45).
A phase III trial demonstrated overall response rates (ORRs)
superior for nab-paclitaxel plus carboplatin compared with con-
ventional solvent-based paclitaxel plus carboplatin in patients
with advanced NSCLC (46). Patient populations, i.e., with squa-
mous histology and those ≥70 years of age, had improved clinical
outcomes with nab-paclitaxel plus carboplatin compared with
solvent-based paclitaxel plus carboplatin (47, 48). No unexpected
differences in toxicity were noted.
CLINICAL EFFICACY
In the multicenter, randomized, Phase III registrational trial,
1052 patients with advanced NSCLC were randomized to receive
first-line weekly nab-paclitaxel (100 mg/m2) plus carboplatin
(AUC 6) every 3 weeks (n= 521) or solvent-based (sb) paclitaxel
(200 mg/m2) plus carboplatin (AUC 6) every 3 weeks (n= 531)
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(46). Patients had to have stage IIIB/IV disease, ECOG PS of 0
or 1 and were previously untreated for metastatic NSCLC. Adju-
vant chemotherapy was permitted if it was completed 12 months
prior to study enrollment. The median age of the patients was
60 years, 75% were male, 81% were white, 73% were smokers,
and 79% had stage IV disease. Patients in the nab-paclitaxel
arm had a significantly greater ORR= the primary endpoint,
compared with the sb-paclitaxel arm (33 vs. 25%, response
rate ratio= 1.313, 95% CI= 1.082–1.593, p= 0.005). Patients
on nab-paclitaxel had longer median PFS= 6.3 vs. 5.8 months,
hazard ratio (HR)= 0.902, 95% CI= 0.767–1.060, p= 0.214).
The median OS for nab-paclitaxel vs. sb-paclitaxel was 12.1
vs. 11.2 months (HR= 0.922, 95% CI= 0.797–1.066, p= 0.271),
respectively.
An exploratory elderly subgroup analysis examined the effi-
cacy and safety of these two regimens in patients ≥70 years of age
enrolled in this phase III trial (46). In these patients (n= 156),
the ORR in the nab-paclitaxel vs. sb-paclitaxel arms was 34 vs.
24% (p= 0.196). A trend toward improved PFS was also noted in
elderly patients with nab-paclitaxel, 8.0 vs. 6.8 months, p= 0.134.
Elderly patients in the nab-paclitaxel arm experienced an impres-
sive 19.9 months median OS compared with 10.4 months in the
sb-paclitaxel arm, p= 0.009.
Another analysis of this phase III trial examined efficacy of
the regimens by histology (48). Patients with squamous NSCLC
(n= 450), achieved a significantly higher ORR, p< 0.001, with
nab-paclitaxel plus carboplatin (41%) vs. sb-paclitaxel plus car-
boplatin (24%) and a 1.2 month improvement in median OS
(10.7 vs. 9.5 months, p=NS). A similar ORR was observed for
nab-paclitaxel plus carboplatin vs. sb-paclitaxel in patients with
non-squamous NSCLC (n= 602, 26 vs. 25%, p=NS), median OS
was 13.1 vs. 13 months in each arm (p=NS). Table 2 shows effi-
cacy outcomes of the intent-to-treat (ITT) population as well as
by age and histology from the phase III trial of nab-paclitaxel plus
carboplatin in NSCLC.
SAFETY AND TOLERABILITY
The most common Grade 3–4 adverse events of the ITT popu-
lation and select subgroups of the phase III trial are shown in
Table S1 in Supplementary Material.
Pre-treatment with antihistamines and/or steroids is required
for sb-paclitaxel and docetaxel to prevent hypersensitivity reac-
tions but not for nab-paclitaxel (39, 42). Much of these reactions
may be solvent-related because both Cremophor EL and polysor-
bate 80 have been associated with hypersensitivity reactions (40);
nab-paclitaxel is not formulated with a chemical solvent (39).
Taxanes are associated with the development of peripheral neu-
ropathy (49). However, in the phase III trial of nab-paclitaxel plus
carboplatin vs. sb-paclitaxel plus carboplatin, patients on nab-
paclitaxel arm experienced significantly less grade 3–4 peripheral
neuropathy compared with the sb-paclitaxel arm (46). Results
based on the FACT-Taxane neuropathy, pain in hands/feet and
hearing loss subscales demonstrated significantly less worsening
of taxane-related symptoms in the nab-paclitaxel arm compared
with the sb-paclitaxel arm, p≤ 0.002 for all (46, 50). The patient-
reported symptom scores were consistent with physician assess-
ments of peripheral neuropathy (50). In addition, patients in
the nab-paclitaxel arm who experienced Grade 3–4 peripheral
neuropathy experienced a faster median time-to-improvement to
Grade 1 (38 vs. 104 days) compared to sb-paclitaxel, respectively.
Taxane use is frequently associated with increased muscle and
joint pains (39, 42). In the phase III study, patients in the nab-
paclitaxel arm experienced significantly less Grade 3–4 arthralgia
and myalgia than patients in the sb-paclitaxel arm (46, 50). In the
phase III trial, patients in the nab-paclitaxel arm experienced sig-
nificantly less Grade 3–4 neutropenia, butmore thrombocytopenia
and anemia than patients in the sb-based arm (46, 50).
CONCLUSION
Nab-paclitaxel represents an important advancement especially as
the treatment options for patients with squamous histology are
Table 2 | Select efficacy outcomes from the Phase III trial of nab-paclitaxel plus carboplatin in NSCLC.
Treatment ITT (41) ≥70 years (42) Histology (43)
SCC NSCC
nab-P/C sb-P/C nab-P/C sb-P/C nab-P/C sb-P/C nab-P/C sb-P/C
n 514 524 74 82 229 221 292 310
ORR (%) 33 25 34 24 41 24 26 25
Response rate ratio 1.313 1.385 1.680 1.034
p-Value 0.005 0.196 <0.001 0.808
Median PFS (months) 6.3 5.8 8.0 6.8 5.6 5.7 6.9 6.5
HR 0.902 0.687 0.865 0.933
p-Value 0.214 0.134 0.245 0.532
Median OS (months) 12.1 11.2 8.0 6.8 10.7 9.5 13.1 13.0
HR 0.922 0.583 0.890 0.950
p-Value 0.271 0.009 0.284 0.611
HR, hazard ratio; IIT, intent-to-treat; nab-P/C, nab-paclitaxel+ carboplatin; NSCC, non-squamous cell carcinoma; NSCLC, non-small cell lung cancer; ORR, overall
response rate; OS, overall survival; PFS, progression-free survival; sb-P/C, solvent-based paclitaxel+ carboplatin; SCC, squamous cell carcinoma.
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limited and elderly patients are often undertreated due to toxicity
concerns among other reasons. Based on these findings and its
greater ease of administration, nab-paclitaxel plus carboplatin
could be considered a first-line standard of care therapy in patients
with advanced NSCLC. Targeted agents active for patients with
squamous histology are in development and in the near future
some of these agents could be assessed in combination with this
regimen.
We must also select for each patient a treatment that is best
suited to his individual comorbidities and treatment toxicities to
ensure the best possible QOL during the last months of his life. Bet-
ter safety and tolerability profile in addition to a greater RR makes
nab-paclitaxel an excellent improvement to a paclitaxel combina-
tion for the first-line treatment of metastatic NSCLC especially for
squamous cell carcinoma.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at http://www.frontiersin.org/Journal/10.3389/fonc.2014.
00177/abstract
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